Iterum Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Iterum Therapeutics plc income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.000.000.000.000.000.040.87
Cost of Revenue0.250.000.000.000.000.000.00
Gross Profit-0.250.000.000.000.000.040.00
Operating Expenses
Research & Development10.4639.9917.6210.7121.0790.7768.65
Selling, General & Administrative7.987.4812.7713.8311.0511.288.78
Operating Expenses18.4447.4730.3824.5432.13102.0677.43
Operating Income-18.70-47.47-30.38-24.54-32.13-102.02-76.56
Other Income/Expense
Interest Income0.000.000.000.000.000.000.00
Interest Expense2.521.432.36-4.53-12.300.000.43
Other Income/Expense-3.3211.14-11.39-61.794.04-0.200.40
Income
Income Before Tax-24.53-37.76-44.13-90.86-51.26-102.69-76.58
Income Tax Expense0.240.610.300.710.740.440.47
Net Income-24.77-38.37-44.43-91.56-52.01-103.13-77.06
Net Income - Continuous Operations-24.77-38.37-44.43-91.560.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-21.73-34.58-39.97-22.43-36.01-102.17-76.02
EBIT-22.01-36.33-41.77-24.54-36.17-102.69-76.16
Depreciation & Amortization0.281.751.802.100.160.150.00
Earnings Per Share
Basic EPS-1.00-3.00-3.00-8.00-33.00-106.00-9.00
Diluted EPS-1.00-3.00-3.00-8.00-33.00-106.00-9.00
Basic Shares Outstanding19.7014.0613.2710.891.600.978.73
Diluted Shares Outstanding19.7014.0613.2710.891.600.978.73